CagriSema would be the first combo GLP-1 if it’s approved, while orforglipron would be the first GLP-1 pill approved for ...

Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the leading companies in the fast-growing GLP-1 weight loss ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...

Eli Lilly’s orforglipron pill helps maintain weight loss after Zepbound or Wegovy injections, with FDA review underway. Learn ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...

NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S.

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

U.S. drug maker Eli Lilly & Co. is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by ...